Arvinas Inc

ARVNNASDAQ · USD
7.79USD0.00 (-0.52%)
839

Arvinas Inc (ARVN) Option Chain

As of September 23, 2026, Arvinas Inc is trading at $7.79, a -0.52% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 66.0%. IV Rank is 22%.

Read more

Tracking the ARVN option chain helps you see every strike and expiry on Arvinas Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Arvinas Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ARVN options activity at a glance. Use our scanner to monitor the ARVN option chain in real time and filter for the ARVN options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ARVN stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the ARVN option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where ARVN stock options are being actively traded and where they are not.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Arvinas Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen ARVN options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of ARVN stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile31.75% Subdued
  • Market cap (M$)509
  • 52 weeks high-46.31%
  • 52 weeks low11.76%
  • Analyst recommendationBuy
    2.31
  • Target price$13.93
    78.82% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-04
  • P/E48.57
  • Future P/E—
  • EPS (ttm)0.16
  • EPS growth next 5 years—

As of September 23, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
2.98000.441.791.153.306.00-23.37—0.750.000.750097.02
22.25601.040.790.453.207.00-10.60—0.200.000.2001577.75
58.20744600.400.000.100.708.00+2.17—0.900.210.6909741.80
85.61132100.300.00—0.309.00+14.940.302.051.21-0.0306314.39
96.632621100.050.00—0.0510.00+27.711.252.252.21-0.46101033.37

As of September 23, 2026

Scan the full option chain in one place

Browse the full ARVN option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial